EPHA2 and glioblastoma: EphA2 drives resistance to the VEGF-a-targeting monoclonal antibody bevacizumab, as a study conducted in glioblastoma patients revealed that patients who developed resistance to bevacizumab had high expression of EphA2, as well as proangiogenic factors such as FGF2, and AGPT2 [71].